Santiago Gisler,  —

Naftopidil treatment causes growth arrest of human lung fibroblasts and reduces fibrotic lesions in mice with idiopathic pulmonary fibrosis (IPF), a study shows. The findings of the study, “Naftopidil reduced the proliferation of lung fibroblasts and bleomycin‐induced lung fibrosis in mice,” were published in the Journal…

Loss of productivity in the workplace is common among patients with fibrotic interstitial lung disease (ILD), and is associated with symptom severity and higher costs, according to data from a Canadian registry study. The study, “Costs of Workplace Productivity Loss in Patients with Fibrotic Interstitial Lung Disease,” was…

Indalo Therapeutics has launched a Phase 1 clinical trial testing the company’s lead antifibrotic candidate IDL-2965 for patients with fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), an inflammatory liver disease. The biopharmaceutical company announced it has now dosed the first healthy volunteer in the…

The pulmonary fibrosis (PF) community is invited to attend the Pulmonary Fibrosis Foundation‘s PFF Summit, which is the largest healthcare meeting on PF, offering data on the latest research. Attendees will get the chance to learn more about the potential of DNA sequencing and targeted therapies to…

Pliant Therapeutics has successfully completed a Phase 1 clinical study assessing its investigational therapy PLN-74809 for idiopathic pulmonary fibrosis (IPF), with results supporting further clinical development of the compound. PLN-74809 is an oral small molecule that selectively inhibits integrins (signaling receptors) called αVβ6 and αVβ1. Results from earlier preclinical…

Blood levels of immune cells called monocytes may help predict disease severity and determine the risk of poor outcomes in patients with idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, a retrospective study suggests. The study, “Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases:…

Envisia Genomic Classifier — a non-invasive diagnostic test developed by Veracyte and used as a complement to high-resolution computed tomography (HRCT) imaging — improves diagnosis of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) compared with HRCT alone, according to a recent study. The findings were published…

Quantification of so-called honeycombing areas (patches of cystic spaces) in the lungs seen through high-resolution computed tomography (HRCT) may be a predictor of mortality in people with idiopathic pulmonary fibrosis (IPF), according to a retrospective analysis. The study, “Quantitative CT analysis of honeycombing area predicts mortality in…

The Pulmonary Fibrosis Foundation (PFF) has opened a new registration cycle for medical centers that wish to join the Foundation’s Care Center Network, with the mission of improving the healthcare quality for people with pulmonary fibrosis (PF). The PFF started the Care Center Network together with the PF…

Exposure to dust in the aftermath of the World Trade Center attacks increased the risk of pulmonary fibrosis (PF) among responders, according to an evaluation of self-reported surveys. Researchers found that higher levels of dust exposure were associated with increased PF incidence. The study, “Pulmonary Fibrosis among World Trade…